Distinguished in Teratocarcinosarcoma

Dr. Alexander Shoushtari

Hematology | Oncology
Memorial Solid Tumor Group
1275 York Ave, 
New York, NY 
Offers Telehealth
16 Years of Experience
Distinguished in Teratocarcinosarcoma
Memorial Solid Tumor Group
1275 York Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Alexander Shoushtari is a Hematologist and an Oncologist in New York, New York. Dr. Shoushtari has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of Teratocarcinosarcoma. His top areas of expertise are Metastatic Uveal Melanoma, Melanoma, Melanoma of the Eye, Liver Embolization, and Gastrostomy.

His clinical research consists of co-authoring 149 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2009
Specialties
Hematology
Oncology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Hamaspik
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

MEMORIAL SOLID TUMOR GROUP
1275 York Ave, New York, NY 10065

Additional Areas of Focus

Dr. Shoushtari has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma
A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 10, 2025
Intervention Type: Other, Drug
Study Drug: Vorinostat
Study Phase: Phase 2
A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination With GSK2141795 in Patients With Advanced Uveal Melanoma
A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination With GSK2141795 in Patients With Advanced Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2025
Intervention Type: Drug, Other
Study Phase: Phase 2
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2025
Intervention Type: Drug
Study Drugs: LXH254, LTT462, Trametinib, Ribociclib
Study Phase: Phase 2
A Phase 2 Study of the ALK Inhibitor Ensartinib for Patients With Melanomas Harboring ALK Alterations or Aberrant ALK Expression
A Phase 2 Study of the ALK Inhibitor Ensartinib for Patients With Melanomas Harboring ALK Alterations or Aberrant ALK Expression
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2025
Intervention Type: Drug, Diagnostic test
Study Drug: Ensartinib
Study Phase: Phase 2
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
Enrollment Status: Withdrawn
Publish Date: July 24, 2024
Intervention Type: Drug
Study Drugs: IMCgp100, Durvalumab, Tremelimumab
Study Phase: Phase 1/Phase 2
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drug: 89Zr-Df-IAB22M2C
Study Phase: Phase 2
A Multicenter Phase 1b Randomized, Placebo-controlled, Blinded Study to Evaluate the Safety, Tolerability and Efficacy of Microbiome Study Intervention Administration in Combination With Anti-PD-1 Therapy in Adult Patients With Unresectable or Metastatic Melanoma
A Multicenter Phase 1b Randomized, Placebo-controlled, Blinded Study to Evaluate the Safety, Tolerability and Efficacy of Microbiome Study Intervention Administration in Combination With Anti-PD-1 Therapy in Adult Patients With Unresectable or Metastatic Melanoma
Enrollment Status: Completed
Publish Date: June 06, 2024
Intervention Type: Drug
Study Drugs: Vancomycin Pretreatment, Nivolumab, SER-401
Study Phase: Phase 1
Phase II Trial of Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Phase II Trial of Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Enrollment Status: Completed
Publish Date: December 06, 2023
Intervention Type: Drug
Study Drug: Crizotinib
Study Phase: Phase 2
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
Enrollment Status: Completed
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: IMCgp100
Study Phase: Phase 1/Phase 2
A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
Enrollment Status: Withdrawn
Publish Date: October 03, 2018
Intervention Type: Radiation, Procedure, Biological, Other
Study Phase: Phase 2
View 9 Less Clinical Trials

149 Total Publications

Clinicopathogenomic Characteristics of Primary and Metastatic Melanomas With RAF1 and BRAF Fusions.
Clinicopathogenomic Characteristics of Primary and Metastatic Melanomas With RAF1 and BRAF Fusions.
Journal: The American journal of surgical pathology
Published: October 17, 2025
Similar Doctors
Distinguished in Teratocarcinosarcoma
Dr. Krzysztof J. Misiukiewicz
Oncology | Hematology
Distinguished in Teratocarcinosarcoma
Dr. Krzysztof J. Misiukiewicz
Oncology | Hematology

Icahn School Of Medicine At Mount Sinai

5 E 98th St, Suite 6, 
New York, NY 
 (1.7 miles away)
212-241-4812
Languages Spoken:
English
See accepted insurances

Krzysztof Misiukiewicz is an Oncologist and a Hematologist in New York, New York. Dr. Misiukiewicz is rated as a Distinguished provider by MediFind in the treatment of Teratocarcinosarcoma. His top areas of expertise are Olfactory Neuroblastoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Teratocarcinosarcoma, Thyroid Cancer, and Tissue Biopsy.

Advanced in Teratocarcinosarcoma
Dr. Nagashree Seetharamu
Oncology | Palliative Medicine | Hematology Oncology
Advanced in Teratocarcinosarcoma
Dr. Nagashree Seetharamu
Oncology | Palliative Medicine | Hematology Oncology

North Shore Health System Medical Faculty Group Practice Inc

27005 76th Ave, 
New Hyde Park, NY 
 (13.0 miles away)
718-470-4449
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nagashree Seetharamu is an Oncologist and a Palliative Medicine provider in New Hyde Park, New York. Dr. Seetharamu is rated as a Distinguished provider by MediFind in the treatment of Teratocarcinosarcoma. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

Advanced in Teratocarcinosarcoma
Dr. Philip A. Friedlander
Oncology
Advanced in Teratocarcinosarcoma
Dr. Philip A. Friedlander
Oncology

Icahn School Of Medicine At Mount Sinai

1555 Ctr Ave, Suite 2, 
Fort Lee, NJ 
 (6.0 miles away)
201-259-7371
Languages Spoken:
English
See accepted insurances

Philip Friedlander is an Oncologist in Fort Lee, New Jersey. Dr. Friedlander is rated as a Distinguished provider by MediFind in the treatment of Teratocarcinosarcoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Squamous Cell Skin Carcinoma, Multiple Myeloma, and Thyroidectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shoushtari's expertise for a condition
ConditionClose
View All 33 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile